Effects of Tranilast on the Urinary Excretion of Kynurenic and Quinolinic Acid under Conditions of L Tryptophan Loading

International Journal of Tryptophan Research

Volumn 6, Issue , 2013, Pages

  Noakes, Rowland R ^a  

^a Queensland Institute of Dermatology and Veracity Clinical Research   (Australia)

Author keywords

kynurenic acid; morphea; quinolinic acid; tranilast; tryptophan

Indexed keywords

EID: 84929875016     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/IJTR.S12797     Document Type: Article

References (19)

1. Wright D.R., Haggins D., Chaffins M., Lokitz M. Eosinophilic fasciitis versus morphea profunda: A spectrum of deep morphea. J Am Acad Dermatol. 2009; 60(3 Suppl 1): AB66.
2. Artlett C.M. Microchimerism and scleroderma: an update. Curr Rheumatol Rep. 2003; 5(2): 154–9.
3. Silver R.M., McKinley K., Smith E.A. et al. Tryptophan metabolism via the kynurenine pathway in patients with the eosinophilia-myalgia syndrome. Arthritis Rheum. 1992; 35(9): 1097–105.
4. Freundlich B., Werth V.P., Rook A.H. et al. L-tryptophan ingestion associated with eosinophilic fasciitis but not progressive systemic sclerosis. Ann Intern Med. 1990; 112(10): 758–62.
5. Blauvelt A., Falanga V. Idiopathic and L-tryptophan-associated eosinophilic fasciitis before and after L-tryptophan contamination. Arch Dermatol. 1991; 127(8): 1159–66.
6. Silver R.M., Sutherland S.E., Carreira P., Heyes M.P. Alterations in tryptophan metabolism in the toxic oil syndrome and in the eosinophilia-myalgia syndrome. J Rheumatol. 1992; 19(1): 69–73.
7. Salter M., Pogson C.I. The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. Biochem J. 1985; 229(2): 499–504.
8. Smith S.A., Pogson C.I. Effects of benserazide and carbidopa on the metabolism of L-tryptophan by isolated rat liver cells. Biochem Pharmacol. 1981; 30(6): 623–8.
9. Joly P., Lampert A., Thomine E., Lauret P. Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. J Am Acad Dermatol. 1991; 25(2 Pt 1): 332–3.
10. Bovenzi M., Barbone F., Betta A., Tommasini M., Versini W. Scleroderma and occupational exposure. Scand J Work Environ Health. 1995; 4: 289–92.
11. Opitz C.A., Litzenburger U.M., Sahm F. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011; 478(7368): 197–203.
12. Zwischenberger B.A., Jacobe H.T. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol. 2011; 65(5): 925–41.
13. Nishigaki T. Mast cell degranulation and its inhibition by an anti-allergic agent tranilast. An electron microscopic study. Virchows Arch, B, Cell Pathol. 1988; 55(5): 311–22.
14. Yamada H., Tajima S., Nishikawa T., Murad S., Pinnell S.R. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J Biochem. 1994; 116(4): 892–7.
15. Taniguchi S., Yorifuji T., Hamada T. Treatment of linear localized scleroderma with the anti-allergic drug, tranilast. Clin Exp Dermatol. 1994; 19(5): 391–3.
16. Stone T.W., Stoy N., Darlington L.G. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci. 2013; 34(2): 136–43.
17. Munn D.H., Zhou M., Attwood J.T. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998; 281(5380): 1191–3.
18. ClinicalTrials.gov. 1-Methyl-D-Tryptophan in Treating Patients with Metastatic or Refractory Solid Tumors that cannot be Removed by Surgery. Identifier NCT00567931. 2013; Available at: http://clinicaltrials.gov/show/NCT00567931. Accessed Aug 30, 2013.
19. Dai X., Zhu B.T. Indoleamine 2,3-dioxygenase tissue distribution and cellular localization in mice: implications for its biological functions. J Histochem Cytochem. 2010; 58(1): 17–28.